

PATIENT INFORMATION

PATIENT NAME: _____ PHONE: _____

DATE OF BIRTH: _____ SEX: ☐ M ☐ F HEIGHT: _____ WEIGHT: _____ ☐ LBS ☐ KG

ALLERGIES: _____ PREFERRED CLINIC: _____

REFERRAL STATUS: ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL**DIAGNOSIS & CLINICAL DOCUMENTATION**☐ E05.00 Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm☐ ICD-10 CODE: _____ DESCRIPTION: _____**REQUIRED DOCUMENTATION**☐ Insurance
Information☐ List of
Medications☐ Tried & Failed
Therapies☐ Most Recent History &
Physical☐ CAS Score☐ Thyroid Panel

PATIENTS WITH PRE-EXISTING DIABETES SHOULD BE UNDER APPROPRIATE GLYCEMIC CONTROL BEFORE RECEIVING TEPEZZA®

MEDICATION ORDER☐ Tepezza® (teprotumumab-trbw) in 100ml – 250ml NS via IV**Initial Dose:**

- 10mg/kg IV over 90 minutes, followed by

Subsequent Dosing:

- 20mg/kg IV every 3 weeks for 7 infusions
 - Infusion #2: infused over 90 minutes
 - Infusion #3-8: infused over 60 minutes as tolerated

☐ REFILLS: _____

Patient to be observed for 30 minutes following the first administration.
In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

PRE-MEDICATIONS**PO**

- ☐ Acetaminophen: 650 mg
- ☐ Cetirizine: 10 mg
- ☐ Diphenhydramine: 25 mg

IV

- ☐ Methylprednisolone: 125 mg
- ☐ Diphenhydramine: 25 mg

☐ OTHER: _____ ☐ PO ☐ IV**PRESCRIBER INFORMATION**

PROVIDER NAME: _____ NPI #: _____

EMAIL: _____ PHONE: _____ FAX: _____

ADDRESS (INCLUDE CITY, STATE, ZIP): _____

SUPERVISING
PHYSICIAN: _____ CONTACT NAME: _____
(IF APPLICABLE)SIGNATURE: _____ DATE: _____
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN